Daniel C. Belostock

My focus

I have extensive experience advising private investment funds and strategic buyers in critical business matters and strategic transactions, acquisitions and divestitures, joint ventures, and strategic alliances.

In addition, I work with private companies and financial sponsors in the management of their portfolio companies on a variety of corporate matters, including add-on acquisitions, strategic ventures, debt financings, and international expansions.

Finally, I have significant experience working on strategic ventures with large corporations, including their preferred stock and convertible debt financings and exit transactions of their portfolio companies.

Representative experience

Daniel joined Nixon Peabody in March 2022. The work outlined below may reflect experience from prior firms.

• Represented Halma plc, a UK global group of life-saving technology companies that provide innovative solutions to key problems facing the world today, in its acquisition of PeriGen, a leader in artificial intelligence, medical, and health technology space
• Represented Carlyle affiliated funds and portfolio companies in several add-on acquisitions for its cloud-based business technology and intelligence platform
• Represented Unilever PLC in strategic acquisitions and divestitures
• Represented Globant, a global, publicly traded digitally native company in add-on acquisitions, including those providing innovative technology solutions in the fraud prevention and identity protection space
• Represented Cerberus Capital in acquisitions in the advertising and food services industries
• Represented BTG plc, the global specialist healthcare company, in various acquisitions, including its acquisition of Novate Medical, a medical device company headquartered in Ireland, and in its investment and option to acquire Veran Medical Technologies, an early lung cancer diagnoses company
• Represented SK Capital Partners in its acquisitions of various portfolio companies in the specialty materials, chemicals, and pharmaceuticals sectors, including Foremark Performance Chemicals, Tri-Tex Co., Noramco, and Tasmanian Alkaloids
• Represented Seaspan Corporation, a leading independent charter owner and operator of containerships, in its acquisition of APR Energy Limited, a global leasing business that owns and operates a fleet of gas turbines and other power generation equipment
• Represented Merck & Co. and Merck Global Health Innovation Fund in several strategic acquisitions and venture financings in the health technology and pharma space
• Represented Comcast Corporation and Comcast Ventures in several strategic acquisition and venture financings in the media tech and infrastructure space

Looking ahead

I see continued competition among and between private and public buyers to win deals in a competitive market environment, particularly in the growing and robust middle-market, with financial sponsors successfully building on platform acquisitions in key sectors. On the strategic side, I see multinational companies rapidly evolving in the deal-making arena, as the pressure to execute on expansion goals in the US and abroad has resulted in increasingly sophisticated corporate development teams.